Centro Oncologico de Excelencia Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
1971
NCT00002455
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
1971

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

corynebacterium granulosum p40 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 3)

Colonic Neoplasms (Phase 3)

Melanoma (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1